Truist Securities Rates Evolent Health (EVH) hold
Truist Securities set a $7 price target for Evolent Health, lowering its rating to hold, a 29.15% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Truist Securities rated Evolent Health, Inc. ($EVH) "hold" with a $7 price target on June 30, 2026.
Since the rating, $EVH is up 1.1% after 1 week, down 41.3% after 1 month and down 15.7% to date (from the $5.42 close on Jun 30, 2026).
EVH
Evolent Health, Inc.
Key Points
- Truist Securities downgraded Evolent Health to a hold rating with a $7 price target on June 30, 2026.
- Truist Securities's $7 price target implies 29.15% upside from Evolent Health, Inc.'s ($EVH) current $5.42 share price.
- Shares of NYSE:EVH traded near $5.77 on Tuesday, with a market cap of about $619.8 million and a forward P/E of 14.3.
- Several insiders, including Peter Grua and Craig Barbarosh, bought 41,096 shares each on June 4, 2026.
Get $EVH trade alerts by text
We text you when insiders, Congress or big funds trade $EVH. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Evolent Health, Inc. alert may contain errors. Disclosures
Truist Securities has downgraded Evolent Health, Inc. (NYSE:EVH) to a hold rating, setting a price target of $7. This change was announced on June 30, 2026, as the firm's analyst Jailendra Singh adjusted expectations for the healthcare company.
Truist Securities vs. the S&P 500
Hypothetical returns from Truist Securities's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Evolent Health
BlackRock, Inc. grew its holdings in Evolent Health by 557,321 shares, ending with 10,888,872 shares valued at approximately $24.8 million. Cadian Capital Management, LP slightly trimmed its stake by 270,982 shares, now holding 10,814,473 shares worth about $24.7 million. Morgan Stanley also reduced its position by 197,044 shares, resulting in 9,081,079 shares valued at $20.7 million. UBS Group AG significantly increased its investment, adding 2,040,743 shares for a total of 8,150,361 shares valued at roughly $18.6 million. Absolute Investment Advisers, LLC boosted its stake by 1,000,000 shares, holding 7,500,000 shares worth about $3.8 million.
Evolent Health, Inc. Stock Up 46.9%
Shares of Evolent Health traded near $5.77 on Tuesday. The company, with a market capitalization of approximately $619.8 million, has a forward P/E ratio of 14.3 and a beta of 0.833. Over the past 52 weeks, the stock has ranged from a low of $2.10 to a high of $12.07. The 50-day moving average is $4.04, and the 200-day moving average is $4.54. Evolent Health maintains a current ratio of 1.32 and a quick ratio of 1.20, with a debt-to-equity ratio of 248.60.
$EVH price target
Evolent Health, Inc. daily closes and this analyst's $7 target. Not advice.
Recent Earnings
Evolent Health reported revenue of approximately $1.89 billion, reflecting a growth of 2.6%. Despite this, the company posted a negative net margin of 26.3% and a return on equity of -65.1%. Earnings per share were not meaningful due to the company's unprofitability. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Evolent Health, Inc.
On June 4, 2026, several insiders, including Peter Grua, Craig Barbarosh, and Russell Monroe Glass, each purchased 41,096 shares. These transactions were not conducted under a Rule 10b5-1 plan.
Analysts Set New Price Targets
On June 30, 2026, Truist Securities downgraded Evolent Health to a hold rating, setting a price target of $7. Previously, the firm maintained a buy rating with the same target on June 12, 2026. The consensus among analysts is a mean target price of $5.88, with 13 analysts providing opinions.
About Evolent Health
Evolent Health, Inc. offers specialty care management services in oncology, cardiology, and musculoskeletal markets across the United States. It provides an integrated value-based care platform for health plan administration and management. Headquartered in Arlington, Virginia, the company is led by CEO Mr. Seth Barrie Blackley and employs approximately 4,200 people.
Bottom Line
Truist Securities' downgrade of Evolent Health to hold reflects a more cautious outlook, setting a $7 price target. Investors track these ratings for insights into market sentiment, though it's important to remember that analyst opinions are just one factor to consider. Evolent Health's financial performance and strategic developments will continue to be key areas of interest.
Related Filing Alerts
Source: Truist Securities's rating change on $EVH (Jun 30, 2026). Written by software, not financial advice. How we make alerts